Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

The Differential Anti-HIV Effect of a New Humic Substance-Derived Preparation in Diverse Cells of the Immune System.

Kornilaeva GV, Siniavin AE, Schultz A, Germann A, Moog C, von Briesen H, Turgiev AS, Karamov EV.

Acta Naturae. 2019 Apr-Jun;11(2):68-76. doi: 10.32607/20758251-2019-11-2-68-76.

2.

Structural and Thermodynamic Analysis of HIV-1 Fusion Inhibition Using Small gp41 Mimetic Proteins.

Jurado S, Cano-Muñoz M, Morel B, Standoli S, Santarossa E, Moog C, Schmidt S, Laumond G, Cámara-Artigas A, Conejero-Lara F.

J Mol Biol. 2019 Aug 9;431(17):3091-3106. doi: 10.1016/j.jmb.2019.06.022. Epub 2019 Jun 27.

PMID:
31255705
3.

Theatre improvisation training to promote social cognition: A novel recovery-oriented intervention for youths at clinical risk for psychosis.

Tang SX, Seelaus KH, Moore TM, Taylor J, Moog C, O'Connor D, Burkholder M, Kohler CG, Grant PM, Eliash D, Calkins ME, Gur RE, Gur RC.

Early Interv Psychiatry. 2019 Jun 9. doi: 10.1111/eip.12834. [Epub ahead of print]

PMID:
31177635
4.

Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1.

Lewis GK, Ackerman ME, Scarlatti G, Moog C, Robert-Guroff M, Kent SJ, Overbaugh J, Reeves RK, Ferrari G, Thyagarajan B.

Front Immunol. 2019 May 10;10:1025. doi: 10.3389/fimmu.2019.01025. eCollection 2019. Review.

5.

A theoretical framework for controlling complex microbial communities.

Angulo MT, Moog CH, Liu YY.

Nat Commun. 2019 Mar 5;10(1):1045. doi: 10.1038/s41467-019-08890-y.

6.

KIR3DL1-Negative CD8 T Cells and KIR3DL1-Negative Natural Killer Cells Contribute to the Advantageous Control of Early Human Immunodeficiency Virus Type 1 Infection in HLA-B Bw4 Homozygous Individuals.

Zhang X, Lu X, Moog C, Yuan L, Liu Z, Li Z, Xia W, Zhou Y, Wu H, Zhang T, Su B.

Front Immunol. 2018 Aug 10;9:1855. doi: 10.3389/fimmu.2018.01855. eCollection 2018.

7.

A High Frequency of HIV-Specific Circulating Follicular Helper T Cells Is Associated with Preserved Memory B Cell Responses in HIV Controllers.

Claireaux M, Galperin M, Benati D, Nouël A, Mukhopadhyay M, Klingler J, de Truchis P, Zucman D, Hendou S, Boufassa F, Moog C, Lambotte O, Chakrabarti LA.

MBio. 2018 May 8;9(3). pii: e00317-18. doi: 10.1128/mBio.00317-18.

8.

HIV transmission from infected CD4+ T cells to allogenic T and dendritic cells is inhibited by broadly neutralizing antibodies.

Ducloy C, Su B, Mayr L, Klingler J, Decoville T, Schmidt S, Laumond G, Salomé N, Bahram S, Moog C.

AIDS. 2018 Jun 19;32(10):1239-1245. doi: 10.1097/QAD.0000000000001834.

PMID:
29683853
9.

In cell mutational interference mapping experiment (in cell MIME) identifies the 5' polyadenylation signal as a dual regulator of HIV-1 genomic RNA production and packaging.

Smyth RP, Smith MR, Jousset AC, Despons L, Laumond G, Decoville T, Cattenoz P, Moog C, Jossinet F, Mougel M, Paillart JC, von Kleist M, Marquet R.

Nucleic Acids Res. 2018 May 18;46(9):e57. doi: 10.1093/nar/gky152.

10.

Non-Neutralizing Antibodies Directed against HIV and Their Functions.

Mayr LM, Su B, Moog C.

Front Immunol. 2017 Nov 20;8:1590. doi: 10.3389/fimmu.2017.01590. eCollection 2017. Review.

11.

The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity.

Amadori C, van der Velden YU, Bonnard D, Orlov I, van Bel N, Le Rouzic E, Miralles L, Brias J, Chevreuil F, Spehner D, Chasset S, Ledoussal B, Mayr L, Moreau F, García F, Gatell J, Zamborlini A, Emiliani S, Ruff M, Klaholz BP, Moog C, Berkhout B, Plana M, Benarous R.

Retrovirology. 2017 Nov 9;14(1):50. doi: 10.1186/s12977-017-0373-2.

12.

Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity.

Mayr LM, Decoville T, Schmidt S, Laumond G, Klingler J, Ducloy C, Bahram S, Zolla-Pazner S, Moog C.

Sci Rep. 2017 Oct 4;7(1):12655. doi: 10.1038/s41598-017-12883-6.

13.

Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status.

Lucar O, Su B, Potard V, Samri A, Autran B, Moog C, Debré P, Vieillard V.

EBioMedicine. 2017 Aug;22:122-132. doi: 10.1016/j.ebiom.2017.07.007. Epub 2017 Jul 11.

14.

A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry.

Fauvelle C, Lambotin M, Heydmann L, Prakash E, Bhaskaran S, Vishwaraman M, Baumert TF, Moog C.

Hepatol Int. 2017 Sep;11(5):440-445. doi: 10.1007/s12072-017-9809-y. Epub 2017 Jul 11.

PMID:
28698985
15.

HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.

Rouers A, Klingler J, Su B, Samri A, Laumond G, Even S, Avettand-Fenoel V, Richetta C, Paul N, Boufassa F, Hocqueloux L, Mouquet H, Rouzioux C, Lambotte O, Autran B, Graff-Dubois S, Moog C, Moris A; ANRS CO21 Cohort.

EBioMedicine. 2017 Jul;21:158-169. doi: 10.1016/j.ebiom.2017.05.029. Epub 2017 May 31.

16.

Model Free iPID Control for Glycemia Regulation of Type-1 Diabetes.

MohammadRidha T, Ait-Ahmed M, Chaillous L, Krempf M, Guilhem I, Poirier JY, Moog CH.

IEEE Trans Biomed Eng. 2018 Jan;65(1):199-206. doi: 10.1109/TBME.2017.2698036. Epub 2017 Apr 25.

PMID:
28459682
17.

Role of nonneutralizing antibodies in vaccines and/or HIV infected individuals.

Mayr L, Su B, Moog C.

Curr Opin HIV AIDS. 2017 May;12(3):209-215. doi: 10.1097/COH.0000000000000357. Review.

PMID:
28422785
18.

Sublingual Priming with a HIV gp41-Based Subunit Vaccine Elicits Mucosal Antibodies and Persistent B Memory Responses in Non-Human Primates.

Bekri S, Bourdely P, Luci C, Dereuddre-Bosquet N, Su B, Martinon F, Braud VM, Luque I, Mateo PL, Crespillo S, Conejero-Lara F, Moog C, Le Grand R, Anjuère F.

Front Immunol. 2017 Feb 1;8:63. doi: 10.3389/fimmu.2017.00063. eCollection 2017.

19.

Langerhans Cells: the 'Yin and Yang' of HIV Restriction and Transmission.

Mayr L, Su B, Moog C.

Trends Microbiol. 2017 Mar;25(3):170-172. doi: 10.1016/j.tim.2017.01.009. Epub 2017 Feb 9.

PMID:
28190635
20.

Low Double-Negative CD3+CD4-CD8- T Cells Are Associated with Incomplete Restoration of CD4+ T Cells and Higher Immune Activation in HIV-1 Immunological Non-Responders.

Lu X, Su B, Xia H, Zhang X, Liu Z, Ji Y, Yang Z, Dai L, Mayr LM, Moog C, Wu H, Huang X, Zhang T.

Front Immunol. 2016 Dec 9;7:579. doi: 10.3389/fimmu.2016.00579. eCollection 2016.

21.

Translational regulation of APOBEC3G mRNA by Vif requires its 5'UTR and contributes to restoring HIV-1 infectivity.

Guerrero S, Libre C, Batisse J, Mercenne G, Richer D, Laumond G, Decoville T, Moog C, Marquet R, Paillart JC.

Sci Rep. 2016 Dec 20;6:39507. doi: 10.1038/srep39507.

22.

Evolvix BEST Names for semantic reproducibility across code2brain interfaces.

Loewe L, Scheuer KS, Keel SA, Vyas V, Liblit B, Hanlon B, Ferris MC, Yin J, Dutra I, Pietsch A, Javid CG, Moog CL, Meyer J, Dresel J, McLoone B, Loberger S, Movaghar A, Gilchrist-Scott M, Sabri Y, Sescleifer D, Pereda-Zorrilla I, Zietlow A, Smith R, Pietenpol S, Goldfinger J, Atzen SL, Freiberg E, Waters NP, Nusbaum C, Nolan E, Hotz A, Kliman RM, Mentewab A, Fregien N, Loewe M.

Ann N Y Acad Sci. 2017 Jan;1387(1):124-144. doi: 10.1111/nyas.13192. Epub 2016 Dec 5. Review.

23.

Occurrence of HIV eradication for preexposure prophylaxis treatment with a deterministic HIV model.

Chang H, Moog C, Astolfi A.

IET Syst Biol. 2016 Dec;10(6):237-243. doi: 10.1049/iet-syb.2016.0008.

24.

[Immune Effects and Mechanisms of HIV-specific Antibodies Against Viral Infection].

Su B, Li L, Mou D, Moog C, Wu H, Zhang T.

Bing Du Xue Bao. 2016 Nov;32(6):830-8. Review. Chinese.

PMID:
30004659
25.

A Cinnamon-Derived Procyanidin Compound Displays Anti-HIV-1 Activity by Blocking Heparan Sulfate- and Co-Receptor- Binding Sites on gp120 and Reverses T Cell Exhaustion via Impeding Tim-3 and PD-1 Upregulation.

Connell BJ, Chang SY, Prakash E, Yousfi R, Mohan V, Posch W, Wilflingseder D, Moog C, Kodama EN, Clayette P, Lortat-Jacob H.

PLoS One. 2016 Oct 27;11(10):e0165386. doi: 10.1371/journal.pone.0165386. eCollection 2016.

26.

Characterization of the interaction between the HIV-1 Gag structural polyprotein and the cellular ribosomal protein L7 and its implication in viral nucleic acid remodeling.

Mekdad HE, Boutant E, Karnib H, Biedma ME, Sharma KK, Malytska I, Laumond G, Roy M, Réal E, Paillart JC, Moog C, Darlix JL, Mély Y, de Rocquigny H.

Retrovirology. 2016 Aug 11;13(1):54. doi: 10.1186/s12977-016-0287-4.

27.

New insights on the phenotype of HIV reservoirs.

Moog C, Mayr L, Tolstrup M.

AIDS. 2016 Jun 19;30(10):1675-6. doi: 10.1097/QAD.0000000000001069. No abstract available.

PMID:
27243776
28.

Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection.

Su B, Peressin M, Ducloy C, Penichon J, Mayr LM, Laumond G, Schmidt S, Decoville T, Moog C.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1187-91. doi: 10.1089/AID.2015.0041. Epub 2015 Sep 10.

29.

Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.

Santra S, Tomaras GD, Warrier R, Nicely NI, Liao HX, Pollara J, Liu P, Alam SM, Zhang R, Cocklin SL, Shen X, Duffy R, Xia SM, Schutte RJ, Pemble Iv CW, Dennison SM, Li H, Chao A, Vidnovic K, Evans A, Klein K, Kumar A, Robinson J, Landucci G, Forthal DN, Montefiori DC, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, Michael NL, Kim JH, Soderberg KA, Giorgi EE, Blair L, Korber BT, Moog C, Shattock RJ, Letvin NL, Schmitz JE, Moody MA, Gao F, Ferrari G, Shaw GM, Haynes BF.

PLoS Pathog. 2015 Aug 3;11(8):e1005042. doi: 10.1371/journal.ppat.1005042. eCollection 2015 Aug.

30.

A Long-Term Model of the Glucose-Insulin Dynamics of Type 1 Diabetes.

Magdelaine N, Chaillous L, Guilhem I, Poirier JY, Krempf M, Moog CH, Le Carpentier E.

IEEE Trans Biomed Eng. 2015 Jun;62(6):1546-52. doi: 10.1109/TBME.2015.2394239. Epub 2015 Jan 20.

PMID:
25615904
31.

Analysis of the HIV eradication phenomenon at the early stage of infection with an extracellular deterministic model.

Chang H, Moog CH, Astolfi A.

Conf Proc IEEE Eng Med Biol Soc. 2014;2014:330-3. doi: 10.1109/EMBC.2014.6943596.

PMID:
25569964
32.

Single-chain protein mimetics of the N-terminal heptad-repeat region of gp41 with potential as anti-HIV-1 drugs.

Crespillo S, Cámara-Artigas A, Casares S, Morel B, Cobos ES, Mateo PL, Mouz N, Martin CE, Roger MG, El Habib R, Su B, Moog C, Conejero-Lara F.

Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18207-12. doi: 10.1073/pnas.1413592112. Epub 2014 Dec 8.

33.

Evaluation of anti-HIV-1 mutagenic nucleoside analogues.

Vivet-Boudou V, Isel C, El Safadi Y, Smyth RP, Laumond G, Moog C, Paillart JC, Marquet R.

J Biol Chem. 2015 Jan 2;290(1):371-83. doi: 10.1074/jbc.M114.616383. Epub 2014 Nov 14.

34.

Mathematical Modeling of HIV Dynamics After Antiretroviral Therapy Initiation: A Review.

Rivadeneira PS, Moog CH, Stan GB, Brunet C, Raffi F, Ferré V, Costanza V, Mhawej MJ, Biafore F, Ouattara DA, Ernst D, Fonteneau R, Xia X.

Biores Open Access. 2014 Oct 1;3(5):233-41. doi: 10.1089/biores.2014.0024. Review.

35.

Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcγRIIa independent mechanism and do not diminish cytokines production.

Lederle A, Su B, Holl V, Penichon J, Schmidt S, Decoville T, Laumond G, Moog C.

Sci Rep. 2014 Aug 18;4:5845. doi: 10.1038/srep05845.

36.

Mathematical modeling of HIV dynamics after antiretroviral therapy initiation: a clinical research study.

Rivadeneira PS, Moog CH, Stan GB, Costanza V, Brunet C, Raffi F, Ferré V, Mhawej MJ, Biafore F, Ouattara DA, Ernst D, Fonteneau R, Xia X.

AIDS Res Hum Retroviruses. 2014 Sep;30(9):831-4. doi: 10.1089/AID.2013.0286. No abstract available.

37.

Which Antibody Functions are Important for an HIV Vaccine?

Su B, Moog C.

Front Immunol. 2014 Jun 18;5:289. doi: 10.3389/fimmu.2014.00289. eCollection 2014. Review.

38.

Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.

Su B, Lederle A, Laumond G, Ducloy C, Schmidt S, Decoville T, Moog C.

J Virol. 2014 Sep;88(18):10975-81. doi: 10.1128/JVI.01748-14. Epub 2014 Jun 25.

39.

Dendritic cell-lymphocyte cross talk downregulates host restriction factor SAMHD1 and stimulates HIV-1 replication in dendritic cells.

Su B, Biedma ME, Lederle A, Peressin M, Lambotin M, Proust A, Decoville T, Schmidt S, Laumond G, Moog C.

J Virol. 2014 May;88(9):5109-21. doi: 10.1128/JVI.03057-13. Epub 2014 Feb 26.

40.

[Anti-HIV antibodies: multiple antiviral activities].

Peressin M, Holl V, Moog C.

Med Sci (Paris). 2014 Jan;30(1):69-75. doi: 10.1051/medsci/20143001016. Epub 2014 Jan 24. Review. French.

41.

Efficient transfer of HIV-1 in trans and in cis from Langerhans dendritic cells and macrophages to autologous T lymphocytes.

Peressin M, Proust A, Schmidt S, Su B, Lambotin M, Biedma ME, Laumond G, Decoville T, Holl V, Moog C.

AIDS. 2014 Mar 13;28(5):667-77. doi: 10.1097/QAD.0000000000000193.

PMID:
24451159
42.

High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers.

Lambotte O, Pollara J, Boufassa F, Moog C, Venet A, Haynes BF, Delfraissy JF, Saez-Cirion A, Ferrari G.

PLoS One. 2013 Sep 23;8(9):e74855. doi: 10.1371/journal.pone.0074855. eCollection 2013.

43.

Generation of HIV-1 potent and broad neutralizing antibodies by immunization with postfusion HR1/HR2 complex.

Dawood R, Benjelloun F, Pin JJ, Kone A, Chanut B, Jospin F, Lucht F, Verrier B, Moog C, Genin C, Paul S.

AIDS. 2013 Mar 13;27(5):717-30. doi: 10.1097/QAD.0b013e32835cfca5.

PMID:
23719346
44.

Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.

Moog C, Dereuddre-Bosquet N, Teillaud JL, Biedma ME, Holl V, Van Ham G, Heyndrickx L, Van Dorsselaer A, Katinger D, Vcelar B, Zolla-Pazner S, Mangeot I, Kelly C, Shattock RJ, Le Grand R.

Mucosal Immunol. 2014 Jan;7(1):46-56. doi: 10.1038/mi.2013.23. Epub 2013 Apr 17.

PMID:
23591718
45.

Neutralizing antibodies inhibit HIV-1 transfer from primary dendritic cells to autologous CD4 T lymphocytes.

Su B, Xu K, Lederle A, Peressin M, Biedma ME, Laumond G, Schmidt S, Decoville T, Proust A, Lambotin M, Holl V, Moog C.

Blood. 2012 Nov 1;120(18):3708-17. doi: 10.1182/blood-2012-03-418913. Epub 2012 Sep 6.

46.

NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients.

Harari A, Rozot V, Cavassini M, Bellutti Enders F, Vigano S, Tapia G, Castro E, Burnet S, Lange J, Moog C, Garin D, Costagliola D, Autran B, Pantaleo G, Bart PA.

Eur J Immunol. 2012 Nov;42(11):3038-48. doi: 10.1002/eji.201242696. Epub 2012 Oct 1.

47.

Challenges for HCV vaccine development in HIV-HCV coinfection.

Lambotin M, Barth H, Moog C, Habersetzer F, Baumert TF, Stoll-Keller F, Fafi-Kremer S.

Expert Rev Vaccines. 2012 Jul;11(7):791-804. doi: 10.1586/erv.12.52. Review.

PMID:
22913257
48.

International network for comparison of HIV neutralization assays: the NeutNet report II.

Heyndrickx L, Heath A, Sheik-Khalil E, Alcami J, Bongertz V, Jansson M, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Ramaswamy M, Sattentau Q, Tolazzi M, Schuitemaker H, Willems B, Wrin T, Fenyö EM, Scarlatti G.

PLoS One. 2012;7(5):e36438. doi: 10.1371/journal.pone.0036438. Epub 2012 May 9.

49.

HIV-1 replication in Langerhans and interstitial dendritic cells is inhibited by neutralizing and Fc-mediated inhibitory antibodies.

Peressin M, Holl V, Schmidt S, Decoville T, Mirisky D, Lederle A, Delaporte M, Xu K, Aubertin AM, Moog C.

J Virol. 2011 Jan;85(2):1077-85. doi: 10.1128/JVI.01619-10. Epub 2010 Nov 17.

50.

Stimulation of HIV-1 replication in immature dendritic cells in contact with primary CD4 T or B lymphocytes.

Holl V, Xu K, Peressin M, Lederle A, Biedma ME, Delaporte M, Decoville T, Schmidt S, Laumond G, Aubertin AM, Moog C.

J Virol. 2010 May;84(9):4172-82. doi: 10.1128/JVI.01567-09. Epub 2010 Feb 10.

Supplemental Content

Support Center